Stem cells are cells in the body that have the ability to differentiate into a variety of different cell types, including muscle tissue, bone marrow and organ-specific cells.

The stem cell therapy market is expected to experience meteoric growth over the next few years. A report from Grand View Research projects that the stem cell market will reach US$18.4 billion by 2028.

‍

Here are 20 innovative stem cell companies in the US:

‍

Aspen Neuroscience

President, CEO, & Board Member - Damien McDevitt

Located in La Jolla, California, Aspen Neuroscience develops autologous cell treatments and tailored medicines for various disorders, beginning with Parkinson's disease. The company's platform combines cutting-edge genomic AI with pluripotent stem cell biology to deliver patient-specific restorative cell therapy that alters disease progression.

‍

Magenta Therapeutics

CSO & Head of Research - Lisa Olson

Located in Cambridge, Massachusetts, Magenta Therapeutics is working on new drugs to boost stem cell transplant, gene therapy, genome editing, and cell therapy's curative abilities. 

‍

Enochian Biosciences

Executive Vice President, Research and Development - Francois Binette

Located in Los Angeles, California, Enochian Biosciences focuses on finding, developing, manufacturing, and marketing gene treatments. It researches and develops cures for infectious diseases and cancer. It is also working on HIV vaccines and treatments, as well as cellular immuno-oncology medicines.

‍

Rubius Therapeutics

CEO - Pablo Cagnoni 

Located in Cambridge, Massachusetts, Rubius Therapeutics is developing red cell therapeutics (RCTs) to treat uncommon disorders, cancer, and autoimmune diseases.

‍

Sana Biotechnology

CBO - Christian Hordo

Located in Seattle, Washington, Sana Biotechnology is dedicated to developing modified cells as therapeutics for patients. They are developing pluripotent stem cells with the goal of replacing any missing or damaged cells in the body, is the next step and creating new delivery methods to deliver any payload to any cell in a precise, predictable, and repeatable manner, opening the way for next-generation in vivo gene therapy. 

‍

Regenexx

President & CEO - Wayne Schellhammer

Located in Des Moines, Iowa, Regenexx has invented a patented orthopedic technique to lower orthopedic costs and improve patient results. The company has created several processing and treatment methodologies and published about half of all studies on the use of mesenchymal stem cells for the treatment of orthopedic injuries, allowing clinicians to treat orthopedic injuries.  

‍

Fate Therapeutics

President & CEO - Scott Wolchko

Located in San Diego, CA, Fate Therapeutics works on cancer and immunological illnesses by developing programmed cellular immunotherapies. NK- and T-cell immuno-oncology initiatives, including off-the-shelf engineered product candidates produced from clonal master iPSC lines, and immuno-regulatory programs, make up the company's cell therapy pipeline.

‍

Cellino

Co-Founder & CEO - Nabiha Saklayen 

Located in Cambridge, Massachusetts, Cellino uses image-guided machine learning, single-cell laser processing, and robotics to create autologous induced pluripotent stem cells (iPSCs) at scale, allowing healthcare professionals to speed up the creation of life-saving medications for patients.

‍

 Protagonist Therapeutics

CEO - Dinesh V. Patel

Located in Newark, California, Protagonist Therapeutics has developed a patented technology platform to meet large unmet medical needs. The company's current pipeline includes Rusfertide (PTG-300), an injectable hepcidin mimetic currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera, a type of blood cancer.

‍

StemoniX

Director, Research and Development - Cassiano Carromeu 

Located in Maple Grove, Minnesota, StemoniX has developed a human-induced cardiac screening tool with the goal of improving and speeding up neurotoxicity research and medication testing. The company's platform develops novel cell-based illness models and scales up bespoke human iPSC disease models for high-throughput screening, allowing scientists to perform research more rapidly and efficiently with better results.

‍

Vertex Pharmaceuticals

President & CEO - Reshma Kewalramani

Located in Boston, Massachusetts, Vertex Pharmaceuticals, researches and develops small-molecule medications for treating critical illnesses. Vertex is diversifying its pipeline beyond cystic fibrosis with gene-editing therapies including CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors for acute and chronic pain utilizing non-opioid treatments.

‍

Intellia Therapeutics

CSO - Laura Sepp-Lorenzino

Located in Cambridge, Massachusetts, Intellia Therapeutics specializes in genome editing. Its primary goal is to produce exclusive CRISPR/Cas9-based therapies with the potential to be curative. Its collaboration with Novartis, includes the ex vivo development of innovative cell therapies using certain ocular stem cells.

‍

Celldex Therapeutics

Senior Vice President and CBO - Ronald Pepin

Located in Hampton, New Jersey, Celldex Therapeutics focuses on the development and commercialization of a variety of immunotherapy technologies as well as other cancer-targeting biologics. Varlilumab, CDX-301, CDX-1140, CDX-0159/Anti-KIT Program, and CDX-527 are among the company's pipeline products.

‍

Celularity

Executive Vice President & CTO - Brad Glover

Located in Florham Park, New Jersey, Celularity, is developing off-the-shelf placental-derived allogeneic cell therapies, such as genetically modified and unmodified NK cells, engineered T cells, including CAR-T cells, and mesenchymal-like adherent stromal cells, for cancer, immunology, infectious, and degenerative diseases.

‍

Century Therapeutics

CEO - Osvaldo (Lalo) Flores

Located in Philadelphia, Pennsylvania Century Therapeutics creates PSCs-derived immune effector cell products designed to target solid tumors and hematological cancers.

‍

ViaCyte

President & CEO - Michael Yang

Located in San Diego, California, ViaCyte, develops innovative cell replacement techniques and regenerative medicine to treat serious human diseases and disorders. The company's therapies are based on two important technological advances: pluripotent stem cell-derived cell replacement therapies and medical device systems for cell encapsulation and implantation.

‍

Curi Bio

CEO - Michael Cho

Located in Seattle, Washington, Curi Bio develops biomimetic cultureware by integrating human cells and data. The company provides products for drug discovery cell and tissue engineering that promotes in vivo maturation which helps drug developers test the efficacy of new drugs.

‍

Frequency Therapeutics

Co-Founder & CSO - Chris Loose

Located in Lexington, Massachusetts, Frequency Therapeutics, that aims to use the body's own biology to heal or cure degenerative disease damage. Its Progenitor Cell Activation method activates progenitor cells in the body to build functional tissue by combining chemicals. 

‍

Garuda Therapeutics

President & Chief Executive Officer - Dhvanit Shah 

Located in Cambridge, Massachusetts, Garuda Therapeutics utilizes mice, zebrafish, and human-induced pluripotent stem cells to develop mechanism-based therapies. These therapies are used to treat patients suffering from immune, bone marrow, and metabolic diseases.

‍

Athersys

CEO - Daniel Camardo

Located in Cleveland, Ohio, Athersys, primary focus is on the development of unique and patented medicines in areas where there is an unmet medical need, particularly in the field of regenerative medicine. Multistem cell treatment is the company's principal product aimed at treating neurological illnesses, cardiovascular disease, inflammatory and immunological disorders, and some pulmonary disorders.

‍

Scispot is on a mission to empower bioentrepreneurs and make workflow automation possible for every life science lab on this planet. To learn more about Scispot and its no-code digital toolkit for lab digitalization and automation, book a demo here.